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ABSTRACT 56 
Background: Osteoarthritis of the knee is a common condition that is expected to rise in the 57 
next two decades leading to an associated increase in total knee replacement (TKR) 58 
surgery.  Although there is little debate regarding the safety and efficacy of modern TKR, up 59 
to 20% of patients report poor functional outcomes following surgery. This study will 60 
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investigate the functional outcome of two TKR; the JOURNEY II Bi Cruciate Stabilised knee, 61 
a newer prosthesis designed to provide guided motion and improve knee kinematics by 62 
more closely approximating a normal knee and the GENESIS II, a proven existing design. 63 
Aim: To compare the change in patient reported outcome scores of the JOURNEY II BCS 64 
and the GENESIS II from pre-operation to six months post-operation. 65 
Methods: CAPAbility is a pragmatic, blinded, two-arm parallel, randomised controlled trial 66 
recruiting patients with primary osteoarthritis due to have unilateral TKR surgery across two 67 
UK hospitals.  Eligible participants (n=80) will be randomly allocated to receive either the 68 
JOURNEY II or the GENESIS II BCS knee prosthesis. Baseline measures will be taken prior 69 
to surgery. Patients will be followed at one week, six to eight weeks and six months post-70 
operatively. Primary outcome is the Oxford Knee Score (OKS) at six months post-71 
operatively. Secondary outcomes include: other patient-reported outcome measures 72 
(PROMs), biomechanical, radiological (computerised tomography, (CT)), clinical efficacy and 73 
safety outcomes. An embedded qualitative study will also investigate patients’ perspectives 74 
via interview pre- and post-surgery on variables known to affect the outcome of TKR 75 
surgery. A sub-sample (n=30) will have additional in-depth interviews to explore themes 76 
identified.  The surgeons’ perspectives on the operation will be investigated by a group 77 
interview after all participants have undergone surgery.  78 
Discussion: This trial will evaluate two generations of TKR using PROMS, kinematic and 79 
radiological analyses and qualitative outcomes from the patient perspective.  80 
Trial registration ISRCTN32315753 (12 December 2017).  81 
Keywords: Total knee arthroplasty; knee replacement; functional ability; knee prosthesis; 82 
kinematics; primary osteoarthritis. 83 
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Introduction 84 
Background and rationale 85 
Osteoarthritis of the knee is a common musculoskeletal condition. The surgical management 86 
of painful end-stage osteoarthritis is by total knee replacement (TKR) which should be 87 
considered before there is prolonged and established functional limitation and severe 88 
pain.[2] Over 100,000 TKRs were performed in the UK in 2019.[3] While TKR frequently 89 
reduces pain and improves physical function in the majority of patients, 20% of patients 90 
report poor functional outcomes post-operatively.[4,5] Such poor outcomes are of 91 
importance to patients and have a considerable financial and service-provision impact on 92 
NHS care. Research is needed to improve post-arthroplasty outcomes for those patients.   93 
There is a paucity of literature regarding the kinematic outcomes of patients following TKR. 94 
However, there is uncertainty as to whether good patient reported outcome measures 95 
(PROMs) are associated with a return to normal kinematics of the TKR knee compared to 96 
the native knee. Movement analysis can be used to examine the change in kinematics 97 
before and after TKR by examining functional movements in activities of daily living. 98 
The long-term success of TKR depends largely on correct component alignment and 99 
accurate ligamentous balancing.[6]  The impact of femoral and tibial component rotation on 100 
flexion gap balance, patellofemoral tracking and normal kinematic function is well-known.[7-101 
9] Complications secondary to poor component alignment have been reported to lead to a 102 
higher rate of revision surgery.[10,11] Computerised Tomography (CT) imaging is a valid 103 
and reproducible technique for accurately measuring TKR component rotation.[12,13] 104 
However, despite CT being widely used to examine implant rotation, the correlation between 105 
rotational alignment, PROMs and kinematic function comparing pre- and post-operative 106 
measurement is unclear.[14,15] It is hypothesised that patients with poor rotational profile 107 
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post-operatively compared to their pre-operative values will have significantly worse 108 
PROMs, movement parameters and patient satisfaction.  109 
We report the protocol of a two-group, parallel RCT comparing patient-reported, surgical and 110 
biomechanical outcomes from a TKR of newer design (the JOURNEY II BCS) designed to 111 
provide improved kinematic outcomes compared to an older design TKR implant (the 112 
GENESIS II).  113 
This protocol (version 2.4, dated 27 February 2019) has been written and reported according 114 
to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 115 
guidance and Checklist[16] (see Additional file 1: SPIRIT 2013 Checklist). 116 
Aims 117 
The principal aim of the trial is to compare the change in PROMs scores of the JOURNEY II 118 
BCS and the GENESIS II knee from pre-operation to six months post-operation. Additional 119 
aims are as follows: 120 
1. To determine if the temporal and spatial parameters of gait, the range of movement and 121 
static and dynamic balance are closer to aged-matched normative data in those receiving 122 
the JOURNEY II BCS compared to those receiving the GENESIS II knee.  123 
2. To monitor the change in function (Aim 1 above) and PROMs of the JOURNEY II BCS 124 
and the GENESIS II knee from post-operation to six months post-operation.  125 
3. From CT scan measures, determine anatomical landmarks and rotational profile around 126 
the native knee and following TKR to ascertain the component rotational position post-127 
operatively compared to anatomical landmarks.  128 
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4. Examine the relationship between rotational values determined by CT scanning with pre- 129 
and post-operative PROMs and movement analysis. 130 
5. To develop knowledge and understanding of patient and surgeon experiences, 131 
perspectives and satisfaction when receiving or implanting the JOURNEY II BCS compared 132 
with the GENESIS II knee, and their experiences of recovery and rehabilitation.  133 
Methods: Participants, interventions, and outcomes 134 
Trial design  135 
This is a pragmatic, triple-blinded, parallel, superiority, randomised controlled trial of the 136 
JOURNEY II BCS (Intervention) versus GENESIS II (Control) in patients with primary 137 
osteoarthritis undergoing TKR. Embedded in the clinical trial is a qualitative investigation of 138 
participants’ confidence in the TKR received and their experiences of the recovery process 139 
in the first six months after surgery. The aim of this is to identify any differences in the 140 
experience of recovery between each type of TKR. Surgeons will also be interviewed to 141 
investigate their perceptions of the surgery and patient’s rehabilitation.  142 
The trial outline is illustrated in Figure 1  143 
Figure 1: CAPAbility trial outline. 144 
 145 
Study setting  146 
Trial sites were pre-selected on the basis of their locality to facilitate data collection (namely 147 
the kinematic assessment). Sites include the Norfolk and Norwich University Hospital 148 
(NNUH), where all patients recruited to the trial will be referred for consideration of TKR. The 149 
NNUH refers a proportion of its TKR patients to Spire Norwich where the operation and 150 
follow-up physiotherapy is delivered. Both hospital are participating in this trial. All CT scans 151 
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will be performed at NNUH. The biomechanical assessment will be undertaken in a 152 
specialist movement analysis laboratory (MoveExLab) at the University of East Anglia 153 
(UEA).  154 
Eligibility criteria 155 
To be eligible for the trial, patients must satisfy the surgeon’s general requirements for a 156 
TKR, meet all inclusion criteria and none of the exclusion criteria listed in Table 1.  157 
Patients will be excluded if they are currently enrolled on an interventional trial involving 158 
surgery, exercise or rehabilitation. Patients can be co-enrolled into studies given prior 159 
agreement from the Trial Management Group (TMG) of both studies. Patients who enter the 160 
study are eligible for entry onto the UK National Joint Registry. 161 
Table 1: Eligibility criteria 162 
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 163 
 164 
Screening 165 
Potential participants will be approached via a single route. Potential participants will be 166 
screened by a member of the clinical team in collaboration with research nurses after having 167 
been added to the orthopaedic clinic waiting list. Potentially eligible patients who meet the 168 
Inclusion Criteria  
• Listed for a primary TKR at the NNUH (may be referred to Spire Norwich for the 
operation)  
• Indication for the TKR is primary osteoarthritis of the knee joint involving one or more 
compartments  
• Aged 18 or over  
• Patient willing to provide full informed consent to the trial including consent for any 
incidental findings to be communicated to their GP  
 
Exclusion Criteria 
• Listed for a single-stage bilateral TKR procedure 
• Severe symptoms in the contralateral knee so as to require staged bilateral knee 
replacements within six months of the primary procedure 
• Fixed flexion deformity of 15 degrees or greater or patients who may require excessive 
resection of the distal femur 
• Clinically assessed uncorrectable varus/valgus deformity of 15 degrees or greater  
• Any co-morbidity which, in the opinion of the investigator, is severe enough to present 
an unacceptable risk to the patient’s safety 
• Inflammatory arthritis 
• Previous septic arthritis in the affected knee joint 
• Previous surgery to the collateral ligaments of the affected knee 
• A contralateral TKR that has been implanted less than one year from the date of 
consultation, or severely painful 
• Patients on warfarin or Novel Oral Anti-Coagulants 
• Will not be resident in the catchment area for NNUH for at least six months post-surgery  
• Undertaking the surgery as a private (non-NHS) patient 
• Patients who, in the opinion of the clinical staff, do not have capacity to consent 
• Patients who are pregnant 
• Unable to understand written and spoken English 
• Patients currently enrolled on an interventional trial involving surgery, exercise or 
rehabilitation. Patients can be co-enrolled into studies not meeting the above criteria 
given prior agreement from the TMG of both studies. Patients who enter the study are 
eligible for entry onto the National Joint Registry and in terms of the Journey II BCS, into 
Beyond Compliance. 
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eligibility criteria, will either be handed a patient information sheet (PIS) if still at the clinic, or 169 
be posted an invitation letter informing them that the trial is taking place and include the PIS. 170 
After having been provided the trial PIS, potential participants will be telephoned by a 171 
research nurse. To minimise the possibility of attrition, appointments for outcome measures 172 
will be agreed with participants when they enter the trial. In addition, members of the 173 
research team will maintain regular contact with participants to ensure attendance at follow 174 
up visits and to monitor any adverse events. 175 
Informed consent 176 
Written informed consent to enter and be randomised into the trial will be taken by a member 177 
of the clinical team and obtained from participants after explanation of the aims, methods, 178 
benefits and potential hazards of the trial. Potential participants will be given as much time 179 
as they need to consider whether or not to provide informed consent. Consent will take place 180 
before any trial-related measures, at a time convenient to the potential participant, preferably 181 
at a time to combine with one or more of the measures to reduce participant visits.  182 
If a participant withdraws prior to surgery, an additional participant will be randomised to 183 
ensure 80 participants complete the surgery. 184 
Patients who, in the opinion of the clinical team, do not have capacity to consent, will be 185 
ineligible. If a participant loses capacity during the course of the trial, they will be withdrawn 186 
from any further assessments, but any data already collected will be retained. Consent will 187 
be re-sought if new information becomes available that affects the participant’s consent in 188 
any way. This will be documented in a revision to the PIS and the participant will be asked to 189 
sign an updated consent form. These will be approved by the ethics committee prior to their 190 
use. A copy of the approved consent form is available from the Norwich Clinical Trials Unit 191 
(NCTU). 192 
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Sample size 193 
Eighty patients will be recruited onto this superiority trial.  The sample size has been 194 
calculated from the Oxford Knee Score (OKS).[17] The OKS ranges from a score of 12 to 195 
60, with 12 being the best outcome. The minimally important clinical difference for OKS is 196 
five[18,19] and a standard deviation of 7.4.[20] For an 80% power, and an assumed dropout 197 
rate of 10%, 80 participants will be randomised to one of the two groups. 198 
Participant timeline 199 
The participant timeline is shown in Figure 1. Where possible trial visits will be combined 200 
with standard clinic visits. Should additional visits be necessary, participants will be 201 
reimbursed for travel costs. 202 
Interventions 203 
All participants will receive routine care provided by the NHS. Pre-operative and peri-204 
operative care is standardised irrespective of implant. 205 
Explanation for choice of comparators (Genesis II versus JOURNEY II BCS) 206 
The GENESIS II TKR system made by Smith and Nephew (Smith & Nephew plc, Watford, 207 
UK) is frequently used in standard practice within the NHS.[3] It has been the standard TKR 208 
within the NNUH and Spire Norwich hospitals for over 10 years. The Genesis II has a 209 
survivorship of over 93% of implants at 15 years[3,21] and offers good health-related quality 210 
of life outcomes.[22] 211 
 212 
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A newer device, JOURNEY II BCS, also manufactured by Smith and Nephew, has been 213 
developed to theoretically provide improved kinematic outcomes compared to the GENESIS 214 
II.[23] These improvements are proposed to include:   215 
• Alteration in the dimensions of the femoral component to reduce soft-tissue strain 216 
and maintain more natural translation and external rotation.   217 
• Reduction in the thickness of the lateral and medial anterior flange of the femoral 218 
component and edge tapering to reducing tension on the iliotibial band (ITB) and IT-219 
patellar bands (ITPB).  220 
• Reduction in the width of the femoral component to limit implant overhang, and 221 
reduction in the mid-flexion thickness of the medial condyle to maintain more 222 
consistent strain on the medial-collateral ligament (MCL) throughout the flexion 223 
range.  224 
• A superior cam position, which serves to decrease femoral rollback in the targeted 225 
ranges of motion, increase femoral external rotation, and lower the point of tibial 226 
post-contact in deep-flexion. 227 
Whilst there is fluoroscopic data to support normal kinematics in early and late flexion,[24] 228 
there is a paucity of evidence exploring these hypotheses for this newer implant.   229 
Surgical flow and training 230 
 231 
Surgeons will be high-volume arthroplasty surgeons who work at both NNUH and Spire 232 
Norwich Hospital.  The standard implant at both sites is the Genesis II TKR system. All 233 
surgeons have used this implant for many years and are very familiar with the surgical 234 
technique. All surgeons and theatre staff have received training on the implantation of the 235 
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JOURNEY II BCS Implant.  All surgeons have undergone training on the JOURNEY BCS II 236 
implant in a cadaveric lab and also undertaken a learning curve with the device until they 237 
were confident with the technique. This was supported by a Smith and Nephew 238 
representative. There are minimal differences in the surgical cuts and technique between the 239 
Genesis II and the JOURNEY BCS II. Participating surgeons felt there was a shallow 240 
learning curve to the JOURNEY BCS II. Both devices are CE marked and will be used within 241 
indication. Smith and Nephew are providing the JOURNEY II BCS at the same price as the 242 
GENESIS II system for this study. 243 
Surgical procedures 244 
Devices will be identified and prepared for the operation by a surgical technician at the 245 
surgery site. 246 
Participants allocated to the intervention device will receive the JOURNEY II BCS prosthesis 247 
while participants allocated to the control condition will receive the GENESIS II prosthesis. 248 
The type of device implanted, and serial number will be recorded on the trial database, by an 249 
unmasked member of the research team.  250 
The surgical procedure will follow the standardised surgical approach and technique. It will 251 
be undertaken through a medial parapatellar approach. In both implants and in every case to 252 
ensure standardisation of technique, a posterior stabilised prosthesis with patella resurfacing 253 
will be used. 254 
It is possible that a decision will be taken prior to or during the operation not to use the 255 
allocated device if, in the opinion of the surgeon, the patient is found to have become 256 
unsuitable for continued participation in the trial. The reasons for an allocated device not 257 
being used will be recorded on the trial database. In this case or if a participant chooses to 258 
withdraw consent for treatment, or follow-up, all data collected up to the point of withdrawal 259 
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will be retained. The standard Norwich Enhanced Recovery Programme (NERP)[25,26] is 260 
used for anaesthetic technique and post-operative recovery.  261 
Post-operative rehabilitation 262 
Post-operative rehabilitation will follow routine clinical care at NNUH and Spire 263 
Norwich.[25,26] Whilst an inpatient, participants will be seen by a physiotherapist for routine 264 
care at least twice daily to progress on a tailored gait re-education and exercise programme 265 
during their hospital admission. This will be recorded in an in-patient hospital rehabilitation 266 
log. Once safe for discharge, patients will be asked to continue a home exercise programme 267 
and gait re-education. This will consist of daily (advised) knee flexion range of motion 268 
exercises and quadriceps strengthening.  269 
At Week 4 post-operatively, all participants will attend an exercise group-based intervention 270 
delivered by a qualified physiotherapist and a physiotherapy assistant. These sessions will 271 
be used to increase participant’s knee range of motion, strength and overall confidence to 272 
undertake more strenuous exercises. Participants will attend this class weekly for two to six 273 
sessions depending on their need. All rehabilitation interventions will be recorded in a post-274 
discharge rehabilitation log. Participants will be encouraged to continue their exercises 275 
which are prescribed within the group as part of a home-exercise programme.  276 
No additional ancillary or post-trial care will be provided (in the absence of adverse event) to 277 
trial participants. 278 
Outcomes 279 
The schedule of enrolment, interventions and assessment is shown in Table 2. The PROMs 280 
will be administered by research nurses apart from the Week 1 follow-up telephone call 281 
undertaken by the research associate performing the qualitative interview. The CT scans will 282 
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be performed at the NNUH by research radiographers and reported by a consultant 283 
radiologist. The biomechanical assessments and qualitative interviews will be performed at 284 
the MoveExLab at UEA. Participants who were unable to attend an assessment 285 
appointments were provided with an alternative appointment. If participants were unable to 286 
attend any alternative assessment appointments, PROMs data were collected during a 287 
telephone call to promotion participant retention and follow-up.  288 
Table 2: Schedule of enrolment, interventions, and assessments. 289 
 Consent Visit  Baseline Pre-Op Op Discharge 
1 week  
Post-op 
6-8 
weeks 
Follow 
Up 
6 month  
Follow-Up 
TIMEPOINT 
Up to 4 
months pre-
operatively 
-2 to -1 
days pre-
operatively 
4 days (+/- 
3 days) 
pre-
operatively 
Day 
0 
On 
discharge 7(+/2) days 
6-8 
weeks 
(+2week
s) 
6 months 
(+ 4 
weeks) 
Enrolment: 
Eligibility screen X        
Informed consent X        
Randomisation   X      
Interventions: 
Knee prosthesis implanted    X   
 
 
Assessments: 
Home Exercise Diary         
Oxford Knee Score (OKS)  X    X X X 
OKS-APQ 
 
X    X X X 
Current Pain Medication  X   X X X X 
Knee Flexion/Extension 
ROM 
 X   X  X X 
Timed Get Up and Go  X     X X 
Timed 6 Minute Walk  X     X X 
3D Motion Capture with 
EMG 
 X     X X 
Static & Dynamic Balance  X     X X 
MVIC  X     X X 
EQ-5D-5L  X    X X X 
UCLA Activity Score  X     X X 
Forgotten Joint Score       X X 
Charlson Comorbidity 
index 
 X     X X 
Complications (Efficacy 
and Safety) 
   X X X X X 
Pain Self-efficacy 
Questionnaire 
 X       
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HADS  X       
CT Study: 
CT Scan 
 
Single scan within the 
consent to operation 
window 
  
 
Single scan within the post op window  
Qualitative Study (Participant): 
Semi Structured Interview  X    X X* X* 
Physiotherapy rehabilitation:  
Post-surgery rehabilitation 
log 
     
Group sessions  
* subset of 30 patient; CT – computerised tomography; HADS – Hospital Anxiety and 290 
Depression Score; MVIC - maximum voluntary isometric contraction; OKS – Oxford Knee 291 
Score; OKS-APQ – Oxford Knee Score Activity and Participation Questionnaire; Pre-Op – 292 
pre-operative; Post-Op – post-operative; ROM – range of motion; UCLA – University of 293 
California Los Angeles 294 
 295 
Primary Outcome 296 
The OKS[17] will be used to assess patient-reported functional status at six months post-297 
surgery. 298 
Secondary Outcomes: Patient Reported Outcome Measures  299 
The Oxford Knee Score (OKS)[17] – Activity and Participation Questionnaire (OKS-300 
APQ),[27] EQ-5D-5L,[28] UCLA Activity score,[29] Hospital Anxiety and Depression Score 301 
(HADS),[30] Forgotten Joint Score (FJS),[31] and 2-Item Pain Self-Efficacy 302 
Questionnaire.[32] 303 
Secondary Outcomes: Clinical Efficacy Outcomes 304 
Clinical efficacy will be evaluated by: 305 
• Surgical-related parameters: need for revision surgery; length of hospital stay and 306 
change in pain medication will be collected during in-patient stay and at all the follow-307 
up time points.  308 
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• Performance-related parameters: knee flexion and extension ranges of movement, 309 
measured at six to eight weeks and six months post-operatively by the research 310 
associate in the MoveExLab (and by the research physiotherapist at baseline as part 311 
of routine care); timed-up-and-go (TUG)[33] and timed six-minute walk test[34] 312 
recorded at the six to eight weeks and six month time-points by the research associate 313 
in the MoveExLab. 314 
Secondary Outcomes: Clinical Safety Outcomes 315 
Complications related to the surgery (e.g. anaesthesia-related problems, bleeding, 316 
morbidities) will be collected from a notes review, prior to discharge, post-discharge, 317 
rehabilitation and follow-up. Additionally, at each visit, participants will be asked if they have 318 
received additional treatment since their surgery/previous visit and what that consisted of.  319 
Secondary Outcomes: Biomechanical Outcomes  320 
All biomechanical measures will be collected in the MoveExLab by the research associate. 321 
3D motion capture using eight cameras (Vicon Motion System, Oxford UK), three built in 322 
force plates (Bertec Corporation, Columbus, Ohio, USA) and surface electromyography 323 
(EMG) (Delsys, Natick, Massachusetts, USA).  Participants will be unshod and asked to 324 
walk at their self-selected speed.  A minimum of three heel strikes from each foot will be 325 
used to construct an average.  326 
1. Overground walking:  Unshod and walking at self-selected speed:  327 
a. Spatiotemporal parameters; speed, cadence, step length, stride length and symmetry  328 
b. Kinematics of bilateral hip, knee and ankle joints  329 
c. Kinetics: moments of bilateral hip, knee and ankle joints and ground reaction forces during 330 
the stance phase  331 
  Page 18 of 44 
 
d. EMG parameters: recruitment patterns of quadriceps: rectus femoris, vastus medialis and 332 
vastus lateralis, hamstrings: semitendinosus, biceps femoris, tibialis anterior, medial and 333 
lateral gastrocnemius. 334 
2. Stair ascent and descent:  335 
a. Spatiotemporal parameters; speed, cadence, symmetry  336 
b. Kinematics of bilateral hip, knee and ankle joints  337 
c. Kinetics: moments of bilateral hip, knee and ankle joints and ground reaction forces from 338 
the bottom step  339 
Static balance measures will be completed on a single in-built force plate (Bertec 340 
Corporation, Columbus, Ohio, USA).  Participants will be instructed to stand with their feet 341 
shoulder width apart for double stance with their eyes closed and then open for 10 seconds. 342 
Three attempts will be recorded. Participants will then be instructed to stand on one leg in 343 
centre of the force plate with their hands on their hips with their eyes open and closed for 10 344 
seconds. Each limb will be tested. Three trials of 10 seconds will be recorded. The time will 345 
be stopped if the participant places the other foot on the floor. Each participant will be given 346 
six attempts at each position.   347 
3. Static balance; measures of Centre of Pressure (CoP) from single and double leg 348 
standing 349 
 a. Anterior-Posterior (AP), Medial-Lateral (ML) and COP path length 350 
 b. AP, ML and COP velocity 351 
 c. AP, ML and COP range and SD 352 
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4. Time-To-Boundary (TTB)[35] 353 
 a. TTB minimum, mean and SD 354 
5. Modified Star Excursion Balance Test (mSEBT)[36] 355 
 a. Anterior, Posteromedial and Posterolateral distance (mm) on both limbs 356 
Secondary Outcomes: Radiological Outcomes 357 
Radiographs 358 
Pre-operative and post-operative conventional semi-flexed AP and lateral radiographs of the 359 
knee will be acquired.  360 
Computerised Tomography 361 
A rotational profile CT protocol will be acquired at the NNUH radiology department under 362 
standard operating procedure. 363 
This will consist of three separate axial acquisitions through the femoral necks, knees and 364 
ankles reconstructed on bone and soft tissue algorithms. The images through the knee will 365 
be split into two acquisitions according to the Berger protocol.[37] The pre-operative CT will 366 
be performed in the time after consent for the study and before TKR. The post-operative CT 367 
is not time sensitive and will be performed any time following surgery.  368 
Two independent observers, radiologists under direct supervision of a senior 369 
musculoskeletal radiologist, will obtain the following measurements from the CT. In the case 370 
of disagreement between the two independent observers, through discussion, the senior 371 
musculoskeletal radiologist will act as adjudicator to ensure agreement is met. 372 
Measurements will include: 373 
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Pre-operative  374 
1. Femoral ante-torsion (degrees) 375 
2. Tibial tubercle-trochlear groove distance (TT-TG) (mm)  376 
3. Tibial torsion (degrees)  377 
Post-operative  378 
1. Femoral ante-torsion (degrees)  379 
2. Femoral component version (degrees)  380 
3. Tibial component version (degrees)  381 
4. Tibial torsion (degrees)  382 
  383 
In the event of an incidental finding being reported, the Clinical Chief Investigator will 384 
organise the necessary clinical follow-up which may include referral to an appropriate 385 
clinician and the organisation of further investigations.  386 
Secondary Outcomes: Qualitative Study 387 
Interviews will be completed either via a telephone call or face-to-face by the research 388 
associate. This flexibility was adopted to promote participant retention and complete follow-389 
up. These will be audio-recorded and transcribed for analysis. 390 
All TKR participants will be invited to take part in an interview and complete a self-efficacy 391 
questionnaire and the HADS at baseline and a telephone call interview at the seven days 392 
(+/- two days) surgery.  393 
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Two additional post-surgery interviews will be carried out with a purposive sample of 394 
participants (N=30), drawn equally from intervention and control groups. Sampling decisions 395 
will be based on the following factors: age; sex; ethnicity; socioeconomic status; OKS; self-396 
efficacy; expectations, mood and symptom management (as ascertained from inspection of 397 
baseline interviews). 398 
The aims of the interviews are to gain in-depth understanding of patient perspectives on 399 
important variables known to affect outcomes of TKR surgery.[5,38-40] Specific themes will 400 
be:  401 
1. To explore patients’ expectations of and hopes for surgery (pre-operative only). 402 
2. To explore patients’ experiences and perspectives on: mood, pain and function – 403 
everyday mobility, participation in work, social roles and activities; surgery and post-404 
operative clinical management; rehabilitation and recovery, and social support.  405 
All surgeons will be invited to consent to a face-to-face interview after the last participant’s 406 
surgery to explore their perspective on using each prostheses and their overall experience of 407 
surgery.  408 
Methods: Assignment of interventions 409 
Allocation 410 
An interactive web randomisation system will be used by a member of the research team 411 
who is not blinded to the intervention. Participants will be randomly assigned to either control 412 
or experimental group with a 1:1 allocation as per a computer-generated randomisation 413 
schedule. Randomisation will occur after the completion of all baseline tests. This will take 414 
place four days (+/- three days) prior to the operation to allow the correct TKR to be made 415 
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available. Randomisation will be stratified by: (a) site (i.e. hospital where surgery is to take 416 
place); and (b) age (<60 years = younger; equal or 60+ years = older).[41,42] 417 
Blinding (masking) 418 
It is not possible to blind the surgeon to the trial intervention. However, the participants, the 419 
physiotherapists, and all staff involved in assessing outcomes will be blinded. Processes will 420 
be in-place to maintain blinding. These will include concealment in a sealed envelope of the 421 
surgery notes mentioning the prosthesis implanted in the patient file.  422 
In the unlikely event of a research nurse accidentally becoming unmasked, the contacts, 423 
assessments, and data entry for that participant will be undertaken by another member of 424 
the research team for the remaining period of trial participation for that participant. 425 
Accidental unmasking will be logged and monitored to ensure appropriate steps are taken to 426 
prevent a re-occurrence.  427 
The clinical staff providing usual care will also be blinded. The decision to unmask a case 428 
will be made when knowledge of an individual’s allocated treatment is required to enable 429 
treatment of a serious adverse event (SAE) which is likely to be caused by the type of device 430 
implanted.  431 
Where possible, requests for emergency unmasking of individuals will be made via the Trial 432 
Manager in agreement with the Clinical Chief Investigator. However, in circumstances where 433 
there is insufficient time to make this request or for agreement to be sought, the treating 434 
clinician can make the decision to unmask immediately. This can be done via the trial 435 
database.  436 
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Methods: Data management and analysis 437 
Data management 438 
Each participant will be given a unique trial Participant Identification Number (PIN). Data will 439 
be entered under the participant’s PIN number onto the central database stored on the 440 
servers based at NCTU. Access to the database will be via unique, individually assigned (i.e. 441 
not generic) usernames and passwords, and only accessible to members of the CAPAbility 442 
trial team at NCTU, and external regulators if requested. The servers are protected by 443 
firewalls and are patched and maintained according to best practice. The physical location of 444 
the servers is protected physically and environmentally in accordance with UEA’s General 445 
Information Security Policy 3 (GISP3: Physical and environmental security).  446 
The database and associated code have been developed by NCTU Data Management, in 447 
conjunction with the CAPAbility trial team. The database software provides a number of 448 
features to help maintain data quality, including; maintaining an audit trail, allowing custom 449 
validations on all data, allowing users to raise data query requests and search facilities to 450 
identify validation failure/missing data. After completion of the trial, the database will be 451 
retained on the servers of NCTU for on-going analysis of secondary outcomes.  452 
The identification, screening and enrolment logs, linking participant identifiable data to the 453 
pseudoanonymised PIN, will be held locally by the trial site. This will either be held in written 454 
form in a locked filing cabinet or electronically in password protected form on hospital 455 
computers. After completion of the trial, the identification, screening and enrolment logs will 456 
be stored securely by the sites for 15 years unless otherwise advised by NCTU. The consent 457 
form will explain that if a participant wishes to withdraw from the study the data acquired 458 
prior to that point will be retained. Reason for withdrawal will be recorded, if given, as will 459 
loss to follow-up. 460 
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Statistical analysis 461 
A full Statistical Analysis Plan (SAP) will be developed between the Trial Statistician and 462 
Chief Investigators and agreed with the trial’s governance committees. All analysis will be 463 
based on the intention-to-treat principle in which all participants will be analysed according to 464 
the group they were allocated, regardless of compliance.  465 
Baseline factors will be summarised by group. All continuous variables will be summarised 466 
by the mean and standard deviation, or if appropriate, the median and interquartile range. 467 
Categorical variables will be summarised with the number and percentage, in each category.  468 
The primary comparison for OKS will be made using a general linear model with the 469 
stratification factors included as fixed-effects. The difference between arms will be 470 
summarised using the mean difference, with 95% confidence intervals presented. A similar 471 
analysis will be undertaken for all other outcome measures.  472 
For the temporal gait parameters and kinematic outcomes, each participant’s 'closeness' to 473 
age-matched normative data will be calculated. This will then be compared between-groups 474 
using a general linear model with the stratification factors included as fixed-effects. This data 475 
will also be presented graphically via scatter and distributional graphs to describe the 476 
deviations from the normative data.  477 
For all the measures of movement listed, a general linear model with the stratification factors 478 
included as fixed-effects will be used to assess for between-group differences. If 479 
appropriate, adjusted analyses will be undertaken by including baseline factors and fixed-480 
effects in the above models. 481 
  Page 25 of 44 
 
Assumptions and sensitivity analysis  482 
All the assumptions will be checked via distribution graphs and tests. If the assumptions are 483 
not valid, transformation will be considered. If none are found, a non-parametric approach 484 
will be used. The pattern of missing or incomplete data will be assessed. If appropriate, 485 
missing data will be imputed. The baseline comparability of the groups will be assessed. If 486 
appropriate, any factor found to be imbalanced and important, will be adjusted for in the 487 
analysis.  488 
Exploratory subgroup analysis will be undertaken by including an interaction in the model to 489 
assess if the effectiveness of the prosthesis is dependent on age or gender.   490 
All analyses will be conducted using Stata and the full SAP will be produced, and approved, 491 
before any comparative analysis is undertaken. 492 
Additional Analyses – CT Scans 493 
All rotational profile measurements will be performed at NNUH under standard operating 494 
procedure on a full diagnostic workstation (Synapse DICOM viewer, Fujifilm, Japan, High 495 
resolution 2K monitors, Radiforce RX340 Eizo, Germany) in the BioImaging Laboratory and 496 
under the supervision of a consultant musculoskeletal radiologist (AT).  497 
Reproducibility 498 
Inter-rater reliability will be assessed using intra-class correlation coefficients and 95% limits 499 
of agreement derived from Bland-Altman plots.  500 
TKR alignment versus native landmarks 501 
The difference between the post-operative component rotational alignment and the pre-502 
operative native landmarks will be assessed using Bland-Altman plots.  503 
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Correlation with PROMS 504 
The correlation between the PROMs and the difference between the post-operative 505 
component rotational alignment and the pre-operative native landmarks will be assessed 506 
using a correlation coefficient. A regression model will also be fitted including the 507 
randomisation group to allow for a potential between-group difference in PROMs.  508 
Correlation with movement analysis 509 
A similar analysis will be undertaken for the correlation between movement analysis and the 510 
difference between the post-operative component alignment and the pre-operative native 511 
landmarks. 512 
Additional Analyses – Qualitative Study  513 
Interview transcripts will be organised using NVivo qualitative data management software 514 
(QSR International, Burlington, Massachusetts, USA). Analysis will follow qualitative content 515 
analysis procedures.[43] Coding and thematic analysis will be carried out independently by 516 
two experienced qualitative researchers. Trustworthiness strategies[44] will be used to 517 
increase the credibility, dependability and transferability of analysis and interpretation. This 518 
will include cross-checking and review of codes and themes; constant comparative method 519 
(hypothesis testing within and across the data set) and deviant case analysis (the use of 520 
‘outliers’ as a resource for understanding and interpretation of data).[45] 521 
Analysis Population and Missing Data 522 
The analysis population are defined as:  523 
a) intention-to-treat: all randomised individuals 524 
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b) per-protocol: all randomised individuals who do not have an alternative TKR during the 525 
follow-up period. Individuals will be included up to the point of the alternative TKR.  526 
c) safety population: all randomised individuals who receive the TKR.  527 
Missing outcomes data will be multiple imputed to increase precision of the treatment effect 528 
estimates. Sensitivity analyses will be conducted to assess the impact of the multiple 529 
imputations and a complete case analysis will also be conducted. All imputations will be 530 
examined to ensure sensible values are being generated. Imputation models will contain 531 
baseline measures, outcome measures and factors predictive of missing data. 532 
No Interim analysis is planned for this study. 533 
Methods: Monitoring 534 
Data monitoring 535 
A TMG has been convened to assist with developing the design, co-ordination and strategic 536 
management of the trial. A Safety Committee will review safety data and act in place of a 537 
Data Monitoring Committee (DMC). Monitoring activities will be undertaken both centrally 538 
and on-site. The frequency, type and intensity of routine and triggered monitoring are 539 
detailed in the Quality Management and Monitoring Plan (QMMP). Ongoing central 540 
monitoring will ensure quality and consistency of data thorough the trial. Details about data 541 
collection and cleaning are described in the Data Management Plan (DMP) 542 
Harms 543 
Safety 544 
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Definitions of harm of the EU Directive 2001/20/EC Article 2 based on the principles of 545 
International Council for Harmonisation (ICH) guideline for good clinical practice (GCP) 546 
apply to this trial. A record of all study-related SAEs, including details of the nature, onset, 547 
duration, severity, relationship to the device, relationship to the operative procedure, 548 
outcome and expectedness will be made on the relevant section(s) of the trial-specific SAE 549 
Form to be sent to the Trial Manager for onward reporting where required. SAEs resulting 550 
from surgery or arthroplasty complications (clinical and safety outcomes) will be reported in 551 
the relevant section of the case report form (CRF). 552 
All non-serious adverse events (AEs) and adverse drug events (ADEs), whether expected or 553 
not, should be recorded in the participant’s medical notes and also reported in the relevant 554 
section of the CRF.  555 
Adverse events do NOT include: 556 
• Readmissions for revision surgery  557 
• Mild (i.e. not lasting more than five days) anaesthetics related complications: 558 
Nausea, vomiting, dizziness, drowsiness, vaso-vagal drop, hypotension and constipation.  559 
• Medical or surgical procedures; the condition that led to the procedure is the adverse 560 
event 561 
• Pre-existing disease or a condition present that was diagnosed before trial entry and 562 
does not worsen 563 
• Hospitalisation where no untoward or unintended response has occurred e.g. 564 
elective surgery, social admissions 565 
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The Safety Committee will be provided with safety data for each treatment arm including 566 
related AEs. The committee will advise on the continuation or early stoppage of the trial in 567 
the unlikely event that there are concerns over harm to participants. The medical care in 568 
response to any harm from the trial participation will be managed by routine NHS care. 569 
Auditing 570 
The Quality Assurance (QA) and Quality Control (QC) considerations for the CAPAbility trial 571 
are based on the standard NCTU Quality Management Policy that includes a formal risk 572 
assessment, and that acknowledges the risks associated with trial conduct and proposals of 573 
how to mitigate them through appropriate QA and QC processes. Risks are defined in terms 574 
of their impact on: the rights and safety of participants; project concept including trial design, 575 
reliability of results and institutional risk; project management; and other considerations. 576 
NCTU staff will review CRF data for errors and missing key data points. The trial database 577 
will also be programmed to generate reports on errors and error rates. Essential trial issues, 578 
events and outputs, including defined key data points, will be detailed in the trial DMP. The 579 
frequency, type and intensity of routine and triggered on-site monitoring will be detailed in 580 
the QMMP. The QMMP will also detail the procedures for review and sign-off of monitoring 581 
reports. In the event of a request for a trial site inspection by any regulatory authority, NCTU 582 
must be notified as soon as possible. 583 
Ethics and dissemination 584 
Research Ethics Approval 585 
The trial is being conducted in accordance with CODEX rules and guidelines for research 586 
and the Helsinki Declaration as well as the ICH Guideline for GCP. The study protocol was 587 
approved by the East of England - Cambridge Central Research Ethics Committee 588 
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(reference 17/EE/0230) prior to the start of the trial. The trial is registered on the 589 
International Standard Randomised Controlled Trials Number (ISRCTN) registry (reference 590 
ISRCTN32315753). Approval was granted by the Health Research Authority (HRA) and 591 
Confirmation of Capacity and Capability to conduct the trial has been provided by the NNUH 592 
Research and Development office. 593 
The NNUH is the trial sponsor and has delegated responsibility for the overall management 594 
of the trial to the Co-Chief Investigators and NCTU including the trial design, coordination, 595 
monitoring and analysis and reporting of results. The standard procedures and policies at 596 
NCTU, a UK Clinical Research Collaboration (UKCRC)-registered trial unit and the study’s 597 
QMMP are followed. A TMG, including lay membership, has been formed to assist with the 598 
design, coordination and strategic management of the trial. An independent safety 599 
committee has also been set up to provide oversight on the trial and to safeguard the 600 
interests of the participants 601 
Protocol amendments 602 
The protocol was amended in August 2017 (before trial start at sites) to improve consistency 603 
and clarity. To that effect, an additional inclusion criterion was added to match the consent 604 
form requiring participants to agree to any incidental findings to be reported to their General 605 
Practitioner. The exclusion criteria relating to the use of the warfarin was also improved by the 606 
addition of novel anti-coagulants therapies which are increasingly used. As part of this 607 
amendment we also changed the stratification criteria from American Society of 608 
Anesthesiologists (ASA) grade[46] and age to site and age as we became aware that ASA 609 
grading is highly subjective and has poor inter-rater reliability. We added the UCLA Activity 610 
Scale[29] as a secondary outcome measure to provide valuable information on the participant 611 
activity levels pre-and post-operatively. The HADS[30] was also added to be taken at baseline 612 
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to inform the purposive sampling for the embedded qualitative study. Symptoms of anxiety 613 
and depression can impact the experience and perception of recovery. The embedded 614 
qualitative study was also simplified by the removal of the physiotherapists’ interview after 615 
agreeing that these would not add relevant information towards the outcome measure due to 616 
recall biases that would be introduced by practical aspects of running these interviews. 617 
Further changes were made in June 2018 allowing further clarifications. This was done 618 
following the removal of the BMI requirement enforced by one of our surgery sites. The 619 
associated exclusion criteria could therefore be removed opening the recruitment to a wider 620 
population and thus improving the representativeness of the study sample as many patients 621 
have a BMI greater than 35. In addition to this, the criteria excluding prior knee surgery was 622 
refined to exclude only previous surgery of the collateral ligaments of the knee as previous 623 
surgery on the cruciate ligaments would not affect the trial outcome as these ligaments are 624 
to be removed during surgery. The clarification of this exclusion criteria also permitted for 625 
previous non-intra-articular knee surgery (e.g. minor procedures around the knee) which 626 
were excluded despite not affecting the trial outcome. The visit windows were also reviewed 627 
as part of these changes to increase the baseline window from - 21 days to - 42 days up to 628 
surgery and to change the six month visit time-frame from +/- two weeks to + four weeks. 629 
The former ensuring enough time for the assessments to take place before randomisation 630 
and the latter that all participants would have a full six months rehabilitation period before 631 
undertaking the last follow-up visits. Additional changes included the addition of the learning 632 
curve details for surgeon training to perform the intervention, the addition of the process for 633 
participants to be informed of their knee allocation at the end of the trial as part of the result 634 
dissemination, the clarification of the non-adherence and non-retention section to confirm 635 
that any data collected up to a participant withdrawal will be retained and the clarification of 636 
the safety reporting period and responsibilities. This amendment also allowed us to update 637 
the compliance section to add the General Data Protection Regulation (GDPR).[47] 638 
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Following on the previous amendment additional modifications were made in August 2018 639 
after the agreement that the recruitment of patients with previous TKR could be allowed as 640 
long as they are over a year old at the time of the consultation and painless, mildly or 641 
moderately painful. This was agreed to create a more representative data set while ensuring 642 
that these participants’ mobility will not be affected by contralateral pain.  643 
Additional changes were made in December 2018 to include the maximum voluntary 644 
isometric contraction (MVIC) of the hamstring and quadriceps muscles on both limbs to 645 
assess the known issue of muscle strength loss after TKR.[48] This biomechanical measure 646 
evaluates post-operative quadriceps and hamstring muscle strength loss and subsequent 647 
recovery in both the non-operative legs and healthy control legs for comparison. The 648 
inclusion criteria were also amended to remove “Patient willing to provide full informed 649 
consent to the trial, including consent for any incidental findings to be communicated to their 650 
General Practitioner”. This does not need to be an inclusion criteria as a potential participant 651 
would not be enrolled on the trial if the consent form, which includes a statement about 652 
communicating findings with the General Practitioner, was not initialled and signed. In 653 
addition the PIS was amended to clarify that baseline data collected for participants that may 654 
not progress to randomisation or surgery, for reasons other than withdrawal, will be retained 655 
and used as observational data. 656 
Furthermore, the protocol was amended in March 2019 to extend the six to eight week visit 657 
window to six to ten weeks to ensure all participants can be seen within the appropriate 658 
window. An additional time point for collecting changes in pain medication was also added to 659 
the participant timeline at discharge from surgery. This will allow for a comparison between 660 
the participant reported pain medications at the Week 1 phone call and what was prescribed 661 
at discharge. 662 
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Consent or assent 663 
Potential participants will be provided with a PIS and given time to read it fully. Following a 664 
discussion with a medical qualified investigator or suitable trained and authorised delegate, 665 
any questions will be satisfactorily answered and if the participant is willing to participate, 666 
written informed consent will be obtained. During the consent process it will be made clear 667 
that the participant is free to refuse to participate in all or any aspect of the trial, at any time 668 
and for any reason, affecting their treatment.  669 
Potential participants who, in the opinion of the clinical team do not have capacity to consent 670 
will be ineligible for this study. If a participant loses capacity during the course of the trial, 671 
they will be withdrawn from the any further assessments but, the data which has already 672 
been collected will be retained.  673 
Consent will be re-sought if new information becomes available that affects the participant’s 674 
consent in any-way. This will be documented in a revision to the patient information sheet 675 
and the participant will be asked to sign an updated consent form. These will be approved by 676 
the ethics committee prior to their use.  A copy of the approved consent form is available 677 
from the NCTU trial team. 678 
No additional consent will be sought for the collection or use of additional participant data or 679 
biological specimens as no such studies are planned. 680 
Confidentiality 681 
Any paper copies of personal trial data will be kept at the participating site in a secure 682 
location with restricted access. Following consent, identifiable data will be kept on the trial 683 
database to allow the MoveExLab staff to contact participants to arrange appointments. Only 684 
authorised trial team members will have password access to this part of the database. 685 
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Confidentiality of participant’s personal data is ensured by not collecting participant names 686 
on CRFs and limiting access to personal information held on the database at NCTU. At trial 687 
enrolment, the participant will be issued a participant identification number and this will be 688 
the primary identifier for the participant, with secondary identifiers of month and year of birth 689 
and initials.  690 
The participant's consent form will carry their name and signature. These will be kept at the 691 
trial site, and a copy sent to NCTU for monitoring purposes. They will not be kept with any 692 
additional participant data. 693 
Declaration of interests 694 
The investigators named on the protocol have no financial or other competing interests that 695 
impact on their responsibilities towards the scientific value or potential publishing activities 696 
associated with the trial. 697 
Access to data 698 
Requests for access to trial data will be considered, and approved in writing where 699 
appropriate, after formal application to the TMG. Considerations for approving access are 700 
documented in the TMG Terms of Reference. The Co-Chief Investigators and Trial 701 
Statistician at NCTU will have access to the full trial dataset. 702 
Dissemination policy 703 
The results of the trial will be disseminated regardless of the direction of effect and will be 704 
reported following the Consolidated Standards of Reporting Trials (CONSORT) 705 
Statement.[49] Ownership of the data arising from the trial resides with the trial team. The 706 
publication policy will be in line with rules of the International Committee of Medical Journal 707 
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Editors.[50] The TMG will decide on the dissemination strategy including presentations, 708 
publications and authorship. 709 
Discussion 710 
This protocol describes a trial that will explore the performance and functional ability of two 711 
types of total knee implants by comparing them on multiple levels.  712 
The use of validated PROMs as both primary and secondary outcomes will allow the 713 
comparison of the Journey II BCS and the Genesis II TKR implants in a standardised 714 
manner widely used in the literature. The addition of biomechanical, radiological, clinical 715 
efficacy and safety outcomes will permit an in-depth comparison of the implants and to fully 716 
assess the performance of both implants’ design in a comprehensive way. This will also 717 
highlight any relationships between each of these individual aspects and inform future study 718 
designs. The biomechanical outcome using everyday movement and detailed anatomical 719 
information from the rotational profile will both provide invaluable and pragmatic information 720 
on the knee implants in situ which will help clinicians in the investigation and management of 721 
participants before and after TKR. Additionally, the embedded qualitative study will 722 
investigate not only participant related constructs associated with both their TKR and 723 
rehabilitation but also provide surgeon’s perspectives. 724 
One of the challenges linked with the collection of varied outcome measures is the 725 
participant visit burden. This has been considered very carefully and the trial has been 726 
designed for study visits to be combined with routine clinical visits or to be undertaken over 727 
the telephone 728 
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